louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04662749: Influence of Intruding Angle on Non-graft Osteotome Sinus Elevation
Official title: Influence of Implant Intruding Angle on Osteotome Sinus Elevation Without Grafting
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Partial-edentulism
Osteotome Sinus Lift
Keywords: osteotome sinus lift
endosinus bone gain
sinus floor configuration
intruding angle
Lead sponsor: Hospital of Stomatology, Sun Yat-Sen University
Sponsor class: OTHER
First posted: 2020-12-10
Enrollment: 46
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who visited Guanghua Hospital of Stomatology, Sun Yat-Sen University from July 2006 to August 2018.

Brief summary: The contour of maxillary sinus matters in osteotome sinus elevation. So does the implant intruding angle between the axis of the implant and the tangent line of the sinus floor contour. The investigators have been engaged in studying the relationship between the outcome of bone formation and the intruding angle, which could guide our clinical decision-making.


Eligibility criteria: Inclusion Criteria:

* Patients with residual bone height \>4mm and osteotome sinus elevation together with simultaneous implant placement without grafting

Exclusion Criteria:

* Smokers or patients with systemic disease.

Primary outcomes:
measure: endosinus bone change
timeFrame: from the time of performing the implanting surgery to the latest recalling period, accessed up to 100 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Hospital of Stomatology, Sun Yat-sen University
state: Guangdong
Study officials:
References:
Clinical trial NCT01395849: Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
Official title: Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Disorders
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-07-18
Enrollment: 2116
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Japanese patients with asthma

Brief summary: The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.


Eligibility criteria: Inclusion Criteria:

* Must use fluticasone and salmeterol for the first time

Exclusion Criteria:

* Patients with hypersensitivity to salmeterol and fluticasone
* Patients with infection which salmeterol and fluticasone is not effective
* Patients with deep mycosis

Primary outcomes:
measure: The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT02122549: Hospital Wearable Defibrillator Inpatient Study
Official title: Hospital Wearable Defibrillator Inpatient Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: In-Hospital Cardiac Arrest
Keywords: In-Hospital Cardiac Arrest
Telemetry
Lead sponsor: Zoll Medical Corporation
Sponsor class: INDUSTRY
First posted: 2014-04-24
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable cardioverter-defibrillators use.

Detailed description: A multi-center prospective study of hospitalized patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period, wearing the HWD1000 hospital wearable defibrillator in order to evaluate caregiver and patient interactions with the device. In addition, ECG signal quality will be reviewed to confirm the HWD1000 safety profile.

Eligibility criteria: Inclusion Criteria:

Patients whom a physician deems at risk of sudden cardiac arrest during the hospitalization period (patients will be monitored using the hospital's telemetry system). Specific inclusion criteria are:

* Hospitalized patients having continuous independent ECG monitoring.
* Patients at risk of sudden cardiac arrest during the hospitalization period as determined by the investigating physician.
* Patient ≥18 years of age (over the legal age of providing consent).

Exclusion Criteria:

* Patients with an active implantable cardioverter-defibrillator.
* Patients with an active unipolar pacemaker.
* Patients with physical or mental conditions preventing them from interacting with or wearing the device as determined by the investigating physician.
* Patients having an advanced directive prohibiting resuscitation.
* Patients having bandages or other clinical condition preventing the HWD use.
* Patients unable to consent.
* Patients having recently experienced an arrhythmic storm.
* Patients prone to paroxysmal supraventricular tachycardia.

Primary outcomes:
measure: Percentage of Time Rhythm Monitoring by the HWD1000 is Compromised Due to ECG Noise.
timeFrame: 24 hours or longer
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
state: California
city: Danbury
country: United States
state: Connecticut
city: Atlantis
country: United States
state: Florida
city: Jupiter
country: United States
state: Florida
city: Iowa City
country: United States
state: Iowa
city: Saint Paul
country: United States
state: Minnesota
city: Richmond
country: United States
state: Virginia
city: Seattle
country: United States
state: Washington
Study officials:
affiliation: Zoll Medical Corporation
name: Steven J Szymkiewicz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02758249: Anesthetic Effect on Immune Cell in Patients With Cancer
Official title: Anesthetic Effect on Immune Cell in Patients With Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2016-05-02
Enrollment: 47
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: BASIC_SCIENCE

Brief summary: Anesthetics agents has an effect on immune response during the cancer surgery.This influence can regulatory to immune activity or cancer cell survival.

The purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

Detailed description: The patients were allocated randomly to receive propofol or sevoflurane. Also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order.

1. immediate before anesthesia induction
2. postoperative 1 hours
3. postoperative 24 hours

Immune cells isolation from patients peripheral blood mononuclear cells. Next, immune cell were co-culture with human cancer cell line (MCF-7) for 24 hours. investigation for immune cell or cancer cell survival by flow cytometry.

Eligibility criteria: Inclusion Criteria:

* patient who was planned to undergo breast cancer surgery.

Exclusion Criteria:

* age \< 20 years old
* history of hypersensitivity reaction in propofol or sevoflurane
* history of previous cancer
* patient with ongoing inflammation

Primary outcomes:
measure: immune cell (NK cell and CD8+ T cell)
timeFrame: up to 24 hours
Secondary outcomes:
measure: cancer cell (MCF-7) apoptosis
timeFrame: Baseline. postoperative 1 hours and 24 hours
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk University Medical Center
Study officials:
affiliation: Konkuk University Medical Center
name: Seong-Hyop Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lim JA, Oh CS, Yoon TG, Lee JY, Lee SH, Yoo YB, Yang JH, Kim SH. The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis. BMC Cancer. 2018 Feb 7;18(1):159. doi: 10.1186/s12885-018-4064-8.
Clinical trial NCT04918849: WhatsApp in India During the COVID-19 Pandemic
Official title: Characterising the Spread of COVID-19 Misinformation Through WhatsApp in India
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Keywords: WhatsApp
Misinformation
Rumours
India
Experience Sampling
Lead sponsor: Yale-NUS College
Sponsor class: OTHER
First posted: 2021-06-09
Enrollment: 1000
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A community sample of the 1000 people from the Indian population

Brief summary: Digital misinformation has been flagged as a major risk of the 21st century, with an estimated cost of $78 billion to the global economy each year. Given this scope, we propose to characterize how misinformation is spread via messenger platforms (e.g. WhatsApp).

Specifically, we seek to:

1. Identify metrics of potential misinformation (Aim 1). This is based on the hypothesis that although message contents are highly private, proxy markers can be used to identify potential misinformation.
2. Understand the base-rate by which misinformation is shared via messaging applications (Aim 2). This is founded on the hypothesis that misinformation is endemic on messaging platforms, and thus needs to be documented.
3. Identify "super spreaders" responsible for sending and receiving a large volume of misinformation (Aim 3). Here, we hypothesise that a small group of super spreaders are responsible for the bulk of misinformation-sharing on messaging applications.

The thrust of this work aligns with both government priorities and the grant's thematic areas, providing actionable findings that are timely amidst a worldwide surge of misinformation.


Eligibility criteria: Inclusion Criteria:

* Lived in India for more than 2 years,
* Currently Living in India
* Owns a WhatsApp account

Exclusion Criteria:

* Not currently living in India
* Below the ages of 21
* Has not lived in India for more than 2 years
* does not own a WhatsApp account
* Does not speak English or Hindi

Primary outcomes:
measure: WhatsApp Usage
timeFrame: 1 week, starting from date after baseline survey completion
measure: Changes in fear with regards the COVID-19 situation across 1 week
timeFrame: 1 week, starting from date after baseline survey completion
measure: Changes in amount of thinking about the COVID-19 situation across 1 week
timeFrame: 1 week, starting from date after baseline survey completion
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Yale-NUS College
Study officials:
References:
Clinical trial NCT04627649: Accuracy of Digital Implant Impression
Official title: Accuracy of Complete-arch Digital Implant Impression With Newly Designed Scan Bodies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Edentulous Jaw
Keywords: dental implant
digital impression
scan body
accuracy
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2020-11-13
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 15 patients are anticipated.

Brief summary: This study aims to investigate the accuracy of complete-arch digital implant impression using newly designed scan bodies with extensional structure.

Detailed description: Fully edentulous patients with 2-6 dental implants are included in this study. For each patient, the follow three impressions are made: conventional splinted open-tray impression, digital impression using scan bodies without extensional structure, and digital impression using scan bodies with extensional structure. The accuracy of the three impressions is compared in an inspection software.

Eligibility criteria: Inclusion Criteria:

* At least 18 years old and able to understand an informed consent
* Fully edentulous jaw
* 2-6 dental implants have been placed in the edentulous jaw
* The implants have been osseointegrated
* Mouth opening larger than 4.5 cm

Exclusion Criteria:

* Poor oral hygiene
* Presence of peri-implantitis or peri-implant mucositis
* Presence of temporamandibular joint disease
* Unwilling to paticipate in the research

Primary outcomes:
measure: accuracy
timeFrame: 0 day
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guanghua school of stomatology, hospital of stomtology, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University
name: Zhuofan Chen, DDS
role: STUDY_DIRECTOR
References:
citation: Chochlidakis K, Papaspyridakos P, Tsigarida A, Romeo D, Chen YW, Natto Z, Ercoli C. Digital Versus Conventional Full-Arch Implant Impressions: A Prospective Study on 16 Edentulous Maxillae. J Prosthodont. 2020 Apr;29(4):281-286. doi: 10.1111/jopr.13162. Epub 2020 Mar 24.
citation: Mizumoto RM, Yilmaz B, McGlumphy EA Jr, Seidt J, Johnston WM. Accuracy of different digital scanning techniques and scan bodies for complete-arch implant-supported prostheses. J Prosthet Dent. 2020 Jan;123(1):96-104. doi: 10.1016/j.prosdent.2019.01.003. Epub 2019 Apr 27.
Clinical trial NCT00784849: Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)
Official title: Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Breast cancer
diagnostic
lymph nodes
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans
Sponsor class: OTHER
First posted: 2008-11-04
Enrollment: 62
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to develope a one-step procedure to perform a biopsy of axillary lymph nodes on the same side as the breast tumor in women diagnosed with breast cancer.

Detailed description: This study proposes the use of a newly developed experimental radioactive dye (radiolabeled methylene blue). On the day of surgery, the patient receives a single injection of the experimental radioactive dye after anesthesia. The injection will be in the location around the breast tumor. The surgeon makes a small cut in the armpit on the side of the cancer and is able to locate the lymh nodes that collect drainage from the cancerous area by detecting lymph nodes with higher radioactivity using a hand-held detector (a Geiger counter-like device) and/or visually identifying lymph nodes stained blue by the dye. These lymph nodes are then removed and analyzed by pathologists for the presence of cancer.

Eligibility criteria: Inclusion Criteria:

* Stage 0,I, II breast cancer
* Clinical node status N0, N1
* No know allergy to iodine, lymphazurin or methylene blue dyes

Exclusion Criteria:

* Patient cannot be pregnant or nursing
* Prisoners will not be eligible
* Women under the age of 18 will not be eligible
* Patients with a known allergy to iodine or methylene blue or lymphazurin blue dyes

Primary outcomes:
measure: The Number of Participants That Have Sentinel Nodes Which Are Radioactive or Blue, or Radioactive and Blue or Have Efferent Blue Lymphatics Leading up to the Sentinel Node(s)
timeFrame: intraoperatively; up to 6 hours
Secondary outcomes:
measure: Safety (Allergic Reaction to Blue Dye)
timeFrame: intraoperatively up to 6 hours
measure: Superficial Skin Necrosis
timeFrame: 2 weeks postoperatively
Other outcomes:
Locations:
city: Lafayette
country: United States
facility: University Medical Center
state: Louisiana
city: New Orleans
country: United States
facility: LSU Interim Hospital
state: Louisiana
Study officials:
affiliation: LSU Health Sciences Center - New Orleans LA
name: Eugene A Woltering, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01762449: Morbidity and Mortality Follow Up for the Scleroderma Lung Study
Official title: Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scleroderma
Keywords: Scleroderma
interstitial lung disease
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2013-01-07
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who participated in the Scleroderma Lung Study

Brief summary: The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.

Detailed description: Retrospective and prospective data will be collected about patients who participated in the Scleroderma Lung Study (SLS). An attempt will be made to include all of the participants of the Scleroderma Lung Study, who were reported as alive at the end of that study.

A total of 158 subjects (79 per treatment arm) were randomized on the original Scleroderma Lung Study. Of those, 109 subjects completed the study. A single telephone interview with the participants to assess the occurrence of severe events and a review of the participant's medical records may be conducted. The outcome information will be combined with information collected about all participants in the SLS study. The data being collected includes information on mortality, development of cancers, development of organ failure, and performance status.

Eligibility criteria: Inclusion Criteria:

* Participation in the Scleroderma Lung Study

Primary outcomes:
measure: Time to death or first organ failure
timeFrame: 9-12 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Duke University
name: Keith Sullivan, MD
role: STUDY_CHAIR
affiliation: University of California, Los Angeles
name: Daniel Furst, MD
role: STUDY_CHAIR
affiliation: University of California, Los Angeles
name: Donald Tashkin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04518449: Medial Border of Laparoscopic D3 Lymphadenectomy for Right Colon Cancer
Official title: the Medial Border Along the Left Side of SMA Versus the Left Side of SMV in Laparoscopic D3 Lymphadenectomy for Right Colon Cancer, a Prospective Cohort Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Colon Cancer
Lead sponsor: Shanghai Minimally Invasive Surgery Center
Sponsor class: OTHER
First posted: 2020-08-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: conlon cancer located at right hemi-colon

Brief summary: This study investigats the gastrointestinal functional outcomes of laparoscopic D3 lymphadenectomy for right colon cancer with the medial border along the left side of superior mesenteric artery (SMA) versus the left side of superior mesenteric vein (SMV). This is a single center, prospective cohort study with a sample size of 264 patients. The primary endpoint is the incidence of diarrhea (evaluated using the Diarrhea Assessment Scale) one month after surgery.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 75 years
* American Society of Anesthesiologists (ASA) score I to III
* A biopsy proven histological diagnosis of colorectal carcinoma
* tumor located at right half of colon
* Undergoing laparoscopic right hemi-colectomy
* preoperative staging cT2-4aN0M0 or cTanyN+M0
* willing to participate and informed consent signed

Exclusion Criteria:

* Pregnant or lactating women
* Synchronous colorectal carcinoma
* History of colorectal cancer or other malignant tumors
* Clinical evidence of metastasis
* Preoperative staging cT1N0 or cT4bNany
* Emergency procedure

Primary outcomes:
measure: incidence of diarrhea
timeFrame: one month after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: